BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short Interest

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 15,720,000 shares, a drop of 9.1% from the December 15th total of 17,290,000 shares. Based on an average trading volume of 2,050,000 shares, the days-to-cover ratio is presently 7.7 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BCRX shares. Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $15.17.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after buying an additional 86,571 shares during the period. Counterweight Ventures LLC boosted its stake in BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after purchasing an additional 79,884 shares during the last quarter. XTX Topco Ltd grew its stake in BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after acquiring an additional 117,607 shares in the last quarter. Seven Eight Capital LP grew its position in shares of BioCryst Pharmaceuticals by 1,407.1% in the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after purchasing an additional 158,358 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 5.5 %

BCRX stock opened at $7.45 on Friday. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The business’s fifty day simple moving average is $7.57 and its two-hundred day simple moving average is $7.61. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -12.21 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period in the previous year, the company posted ($0.19) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% on a year-over-year basis. Research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.